drugset / Trial / NCT04601116
The MASTER Study (MAmmary Cancer STatin ER Positive Study)
Phase 3
Recruiting
3360 enrolled
Aarhus University Hospital
Aalborg University Hospital · collabBornholms Hospital · collabHerning Hospital · collabHospital of Southern Jutland · collabNaestved Hospital · collabNordsjaellands Hospital · collabOdense University Hospital · collabRigshospitalet, Denmark · collabUniversity of Copenhagen · collabVejle Hospital · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Given the compelling evidence supporting a protective effect of statins on breast cancer recurrence, calls for prospective clinical trials have been expressed. In this trial - the MASTER trial - we hypothesize that the addition of statin treatment to the current breast cancer treatment will improve the prognosis of women with early breast cancer. This trial is designed as follows: a randomized, multicenter, double-blind, placebo-controlled comparison of standard (neo)adjuvant therapy plus placebo versus standard (neo)adjuvant therapy plus atorvastatin in patients with early breast cancer.
Timeline
- Start
- 2021-01-04
- Primary completion
- 2025-01-01
- Completion
- 2035-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Atorvastatin | Small molecule | 80 mg | Oral |